Key result
Elevated cardiac injury markers strongly predicted ICU admission in hospitalized heart failure patients with COVID-19, led by troponin-I and myoglobin.
Why the study?
Patients with pre-existing chronic heart failure face increased risk of decompensation and cardiac damage during SARS-CoV-2 infection, motivating a detailed evaluation of biological parameters and cardiac injury markers to predict ICU admission from initial hospital presentation.
Cohort (n=360)
No
Answers are grounded in this paper and cite their sources.
Retrospective study demonstrates elevated cardiac injury markers predict intensive care unit admission in heart failure patients with COVID-19, highlighting the value of early risk triage.
COVID-19 has been associated with cardiovascular consequences, including myocardial infarction, thromboembolic events, arrhythmia, and heart failure. Numerous overlapping mechanisms, such as the IL-6 dependent cytokine storm and unopposed angiotensin II stimulation, could be responsible for these consequences. Cardiac damage is hypothesized to be a consequence of the direct viral infection of cardiomyocytes, resulting in increased metabolic demand, immunological activation, and microvascular dysfunction. Patients with pre-existing chronic heart failure are therefore at increased risk of decompensation, further heart damage, and significant health deterioration. Based on the aforementioned assumptions, we developed a study aiming to provide a detailed description of changes in biological parameters and cardiac injury markers of patients with heart failure and SARS-CoV-2 infection by correlating them with the clinical presentation and COVID-19 vaccination status, to predict the probability of ICU admission based on their initial hospital presentation. A two-year retrospective study was performed on heart failure patients with a history of SARS-CoV-2 infection and detailed records of biological biomarkers; a total of 124 eligible patients with COVID-19 and 236 without COVID-19 were recruited. Patients with heart failure and SARS-CoV-2 infection had significantly elevated baseline biological parameters and cardiac markers compared to those without COVID-19. Several cardiac injury markers were identified as significant independent risk factors for ICU admission: CK-MB (HR = 4.1, CI [2.2-6.9]), myoglobin (HR = 5.0, CI [2.3-7.8]), troponin-I (HR = 7.1 [4.4-9.6]), troponin-T (HR = 4.9, CI [1.7-7.4]). The elevation of a basic panel of acute inflammation markers (CRP, IL-6, fibrinogen), D-dimers, and BNP was also a significant risk factor. The follow-up of survivors at four weeks after viral clearance determined a worsened clinical picture by NYHA classification, worsened cardiac ultrasound findings, and a mild improvement in cardiac and inflammatory markers. Increased levels of myocardial damage parameters in association with cardiac ultrasound findings and basic inflammatory markers may enable early risk assessment and triage in hospitalized heart failure patients infected with SARS-CoV-2.
No takes yet. Share an insight, caveat, or question.
Pilut et al. (2022) conducted a cohort in Heart failure with SARS-CoV-2 infection (n=360). SARS-CoV-2 infection and elevated cardiac injury biomarkers (Troponin I) vs. Heart failure patients without SARS-CoV-2 infection or normal biomarker levels was evaluated on Intensive care unit (ICU) admission predicted by elevated Troponin I (HR 7.1, 95% CI 4.4-9.6, p=<0.001). Elevated cardiac injury markers strongly predicted ICU admission in hospitalized heart failure patients with COVID-19, led by troponin-I and myoglobin.
Synapse has enriched 10 related papers. Consider them for comparative context: